Agree re costs and to a certain extent Atcor.The clinical trial segment is worth the current MC on its own.
Though it won't shoulder all the burden:
The Board and executive management team are now actively reviewing and implementing alternative capital raising initiatives to ensure that the Company’s commercial sales, operational plans, the commercial launch of the Pulse, and progress on the FDA submission for the CONNEQT Band all continue to progress as planned.
Actively reviewing and implementing alternative capital raising initiatives for all sales and operational activities including launch of Pulse and progressing FDA submission for CONNEQT Band.
That's a decent chunk of forward work and time.
The wording is confident (wouldn't expect anything less!) and suggests they have more than one 'potential' source of funds on the table.
Just a matter of waiting to see how it all unfolds.
Never a dull moment that's for sure. Sometimes near-death experiences are the making of a company.
Add to My Watchlist
What is My Watchlist?
